Secondary Logo

Journal Logo

Institutional members access full text with Ovid®

Developing patient-reported outcome measures for pain clinical trials: IMMPACT recommendations

Turk, Dennis C.a,*; Dworkin, Robert H.b; Burke, Laurie B.c; Gershon, Richardd; Rothman, Margarete; Scott, Janec; Allen, Robert R.f,1; Atkinson, Hampton J.g; Chandler, Julieh; Cleeland, Charlesi; Cowan, Pennyj; Dimitrova, Rozalinak; Dionne, Raymondl,2; Farrar, John T.m; Haythornthwaite, Jennifer A.n; Hertz, Sharonc; Jadad, Alejandro R.o; Jensen, Mark P.a; Kellstein, Davidp,3; Kerns, Robert D.q,r; Manning, Donald C.s; Martin, Susant; Max, Mitchell B.l,2; McDermott, Michael P.b; McGrath, Patricku; Moulin, Dwight E.v; Nurmikko, Turow; Quessy, Stevex; Raja, Srinivasan; Rappaport, Bob A.c; Rauschkolb, Christiney,4; Robinson, James P.a; Royal, Mike A.z,5; Simon, Leeaa; Stauffer, Joseph W.ab,6; Stucki, Geroldac; Tollett, Janead; von Stein, Thorstenae,7; Wallace, Mark S.g; Wernicke, Joachimaf; White, Richard E.ag; Williams, Amanda C.ah; Witter, Jamesc; Wyrwich, Kathleen W.ai

doi: 10.1016/j.pain.2006.09.028
Review and recommendations
Buy

aUniversity of Washington, Seattle, WA 98195, USA

bUniversity of Rochester School of Medicine and Dentistry, Rochester, NY, USA

cUnited States Food and Drug Administration, Rockville, MD, USA

dNorthwestern University, Chicago, IL, USA

eJohnson and Johnson, Raritan, NY, USA

fAstraZeneca, Wilmington, DE, USA

gUniversity of California San Diego, La Jolla, CA, USA

hMerck and Company, Blue Bell, PA, USA

iUniversity of Texas, M.D. Anderson Cancer Center, USA

jAmerican Chronic Pain Association, Rocklin, CA, USA

kAllergan, Inc, Irvine, CA, USA

lNational Institute of Dental and Craniofacial Research, Bethesda, MD, USA

mUniversity of Pennsylvania, Philadelphia, PA, USA

nJohns Hopkins University, Baltimore, MD, USA

oUniversity Health Network and University of Toronto, Toronto, Canada

pNovartis Pharmaceuticals, East Hanover, NJ, USA

qVA Connecticut Healthcare System, West Haven, CT, USA

rYale University, New Haven, CT, USA

sCelgene Corporation, Warren, NJ, USA

tPfizer Global Research and Development, Ann Arbor, MI, USA

uDalhousie University, Halifax, Nova Scotia, Canada

vLondon Regional Cancer Centre, London, Ont., Canada

wUniversity of Liverpool, Liverpool, UK

xGlaxoSmithKline, Research Triangle Park, NC, USA

yJohnson & Johnson, Raritan, NJ, USA

zAlpharma, Elizabeth, NJ, USA

aaHarvard Medical School, Boston, MA, USA

abAlpharma, Piscataway, NY, USA

acUniversity of Munich, Munich, Germany

adUS Department of Veterans Affairs, Washington, DC, USA

aeNeurogesX, Inc, San Carlos, CA, USA

afEli Lilly and Co., Indianapolis, IN, USA

agEndo Pharmaceuticals Inc., Chadds Ford, PA, USA

ahSt. Thomas Hospital, London, UK

aiSaint Louis University, St. Louis, MO, USA

*Corresponding author. Tel.: +1 206 616 2626; fax: +1 206 543 2958.

E-mail address:Turkdc@u.washington.edu

1Present address: Wyeth, Madison, NJ, USA.

2Present address: The National Institute of Nursing Research, Bethesda, MD, USA.

3Present address: Wyeth Consumer Healthcare, Madison, NJ, USA.

4Present address: Johnson and Johnson, Titusville, NJ, USA.

5Present address: Solstice Neurosciences, Malvern, PA, USA.

6Present address: Alpharma, Piscataway, NJ, USA.

7Present address: Tercica, Brisbane, CA, USA.

Submitted January 9, 2006; revised May 22, 2006; accepted September 18, 2006.

© 2006 Lippincott Williams & Wilkins, Inc.
You currently do not have access to this article

To access this article:

Note: If your society membership provides full-access, you may need to login on your society website